Using wearable devices and AI to predict COPD flare-ups
Early Prediction of Acute Exacerbations of COPD Using Wearable and Portable Remote Monitoring Technology With AI/ML Empowered Platforms: A Prospective Clinical Study
McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT06802003
This study is testing if wearable devices and daily symptom reports can help predict flare-ups in people with COPD using artificial intelligence.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre (other) |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT06802003 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather real-time physiological data from patients with chronic obstructive pulmonary disease (COPD) using wearable devices and handheld oscillometers. Participants will report their symptoms daily, and the collected data will be utilized to develop and validate artificial intelligence and machine learning models for predicting acute exacerbations of COPD. The study also seeks to establish a new classification system for the severity of these exacerbations based on the relationships between physiological measurements and self-reported symptoms.
Who should consider this trial
Good fit: Ideal candidates include adults aged 40 and older with a history of COPD exacerbations and a significant smoking history.
Not a fit: Patients without a COPD diagnosis or those unable to operate the required devices will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable early prediction of COPD exacerbations, potentially improving patient management and outcomes.
How similar studies have performed: Other studies have shown promise in using wearable technology and AI for monitoring chronic conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males/females, age ≥ 40, former/current smokers with ≥10 pack-year smoking history * FEV1/FVC \< 0.7, with 80% \< FEV1 ≤50% (moderate, 'GOLD 2') 50% \< FEV1 ≤ 30% (severe, 'GOLD 3') or FEV1 \< 30% (very severe, 'GOLD 4') COPD * History of 2 or more exacerbations in the preceding 12 months requiring corticosteroids, antibiotics, or both * Ability to provide informed consent * Ability to access internet at least once daily Exclusion Criteria: * No existing COPD diagnosis * Any medical/cognitive/functional condition which renders inability to operate research equipment/devices, and/or to complete daily symptom response
Where this trial is running
Montreal, Quebec
- McGill University Health Centre — Montreal, Quebec, Canada (RECRUITING)
Study contacts
- Study coordinator: Bryan A. Ross, MD, MSc (Physiol), MSc (Epi)
- Email: bryan.ross@mcgill.ca
- Phone: (514) 843-1465
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD, AE COPD, acute exacerbation of COPD, chronic obstructive pulmonary disease, artificial intelligence/machine learning, remote patient monitoring, biometric wearable device, oscillometry